Navigation Links
QLT announces first quarter 2008 Visudyne(R) sales
Date:4/21/2008

VANCOUVER, April 21 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$36.5 million for the quarter ended March 31, 2008. This represents a decrease of 40.4% over sales in the first quarter of 2007. Sales in the U.S. were $9.3 million, up 10.6% from the prior-year first quarter, while sales outside the U.S. were $27.2 million, down 48.5% from the prior year. The drop in Visudyne sales was primarily due to the approval and reimbursement in Europe of alternative therapeutics for age-related macular degeneration.

QLT will release its full financial results on Friday, April 25, 2008, at 7:30 a.m. ET.

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne and Eligard(R) and future product opportunities. For more information, visit our web site at http://www.qltinc.com.

Conference call information

QLT Inc. will hold an investor conference call to discuss first quarter 2008 results on Friday, April 25 at 8:30 a.m. ET (5:30 a.m. PT). The call will be broadcast live via the Internet at http://www.qltinc.com. To participate on the call, please dial 1-800-319-4610 (North America) or 604-638-5340 (International) before 8:30 a.m. ET. A replay of the call will be available via the Internet and also via telephone at 1-800-319-6413 (North America) or 604-638-9010 (International), access code 7157, followed by the "#" sign.

A full explanation of how QLT determines and recognizes re
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Breckenridge Announces Approval of Generic Activella(R)
2. Accenx Technologies Announces New Leadership in Sales and Marketing Division
3. VNUS Medical Technologies, Inc. Announces the Hiring of Don Todd as Vice President of Marketing
4. CardiacAssist, Inc. Announces Five New TandemHeart Centers of Excellence
5. HeartWare Announces Move to an Expanded, Upgraded Manufacturing Facility
6. GHX Announces 2008 Best In Class Award Winners
7. AtriCure Announces Web Cast and Conference Call of First Quarter 2008 Financial Results
8. Huifeng Bio-Pharmaceutical (HFGB) Announces Participation in the 59th PHARMCHINA Expo
9. Zimmer Announces New Compliance Model
10. The Alliance for Lupus Research Announces 2008 Grantees
11. TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , WASHINGTON, Dec. 2 /PRNewswire-USNewswire...today on " Supplement Safety Now ," an initiat...ther organizations, the Council for Responsible Nu...senting the dietary supplement industry, issued th...e Mister , President and CEO: ,, "We share t...
(Date:12/2/2009)...t improvement seen for advanced cases, study finds...-- In the past two decades, survival rates for adv...ve improved modestly, a new study has found. , ...ients diagnosed with stage 4 non-small cell lung c...nformation was in the U.S. National Cancer Institu...
(Date:12/2/2009)...er treatment prolongs life remains unclear, resear...ay News) -- New research suggests that enzyme repl... lives of people with Fabry disease, a rare illnes... The progressive disease, linked to the lack of an...the body, can be fatal because it boosts the risk ...
(Date:12/2/2009)... , WHITE PLAINS, N.Y., Dec. 2 /PRNewswire-USN... present their findings in blood cancer research a...conference in New Orleans December 4-8, 2009. ,...p; Lymphoma Society (LLS) experts, including Chief... Vice President of Patient Services Hildy Dillon, ...
(Date:12/2/2009)... , Ruling by federal government ends ..., LOS ANGELES, Dec. 2 M...of Kaiser Permanente facilities across Southern Ca...n the National Union of Healthcare Workers (NUHW)....o join NUHW in February, but SEIU delayed the elec...
Breaking Medicine News(10 mins):Health News:CRN Responds to 'Supplement Safety Now' Initiative 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 3Health News:Gains Made in Lung Cancer Survival 2Health News:Labor Board OKs 2,300 Kaiser Professionals to Quit SEIU and Join National Union of Healthcare Workers 2
... for consumers that it was just five years ago, th...t foods. There are more than 5,000 reduced fat fo... fat-free or low-fat milk// products and salad dre...ic functions like retaining moisture or modifying ...
...earchers have found that the bone marrow cell tran...ers in the US have been studying the ability of hu... to restore function in brain-damaged rats. Animal... received skin cells, those animals that were inje...
...nfirmed that a compound modelled on a substance fo... cancer. Previous research has suggested that sulf...egetables, can help prevent cancer. It does so by ...r drug development - and the amount of broccoli yo...
... found that eating more calories and fats may incr... some people. Previous research has shown that mic...r. //Researchers feel this is because of fewer des...ase the damage done by particles found in brains o...
...that governments and societies must implement revo...d preventive medicine if they want to ensure the h...li, Henry J. Miller, and Stanley Falkow, felt that... implementation, write. However, the future of...
...tion called contact dermatitis may benefit from ri...nd tomatoes, according to the results of a small s...ence inflamed, red, itchy, scaly skin when they co... realize foods can also trigger it. In t...
Other Medicine News:Health News:Diet combined to Alzheimer's disease 2
(Date:12/2/2009)...K, Dec. 2 Reportlinker.com announc...in its catalogue: ,, Cardiac Pacemakers - A W...ker.com/p0164335/Cardiac-Pacemakers---A-World-Mark...te a major segment in a rapidly expanding cardiova...akers market is characterized by relatively mature...
(Date:12/2/2009)...Pa., Dec. 2 Cephalon, In...led a lawsuit in U.S. District Court in Delaware a...ment of U.S. Patent Nos. 7,132,570 (the ",570 Pate...the ",516 Patent") for the Cephalon product NUVIGI...s a three-year period of marketing exclusivity for...
(Date:12/2/2009)...K, Dec. 2 Reportlinker.com announc...in its catalogue: ,, Multiple Myeloma Therape...ttp://www.reportlinker.com/p0164271/Multiple-Myelo... ,, Given the severity, and relentless relapses...rapies and treatments to battle the disease and im...
Breaking Medicine Technology:Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 2Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 3Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 4Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 5Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 6Cynosure to Present at the Maxim Group Growth Conference 57944 1Cynosure to Present at the Maxim Group Growth Conference 57944 2Glaucoma Tied to Gene Variants in Blacks 57942 1Glaucoma Tied to Gene Variants in Blacks 57942 2Milliman Announces the Opening of a New Office in San Juan Puerto Rico 57938 1Milliman Announces the Opening of a New Office in San Juan Puerto Rico 57938 2
..., April 18, 2007,/PRNewswire-FirstCall/ -- Pharmac...ical studies, one identifying a functional,biomark...tor and,another demonstrating preclinical anti-tum...) inhibitor compounds. The data were,presented at ...),2007 Annual Meeting being held this week in Los ...
.../PRNewswire-FirstCall/ --,ONCONASE (ranpirnase), A...e potential as a chemopreventive agent, according ...Carbone M.D., Ph.D.,at this week,s American Assoc..., In a series of poster presentations, Dr. Carbone...stos exposure and its link to,malignant mesothelio...
Other Medicine Technology:Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 2Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 3Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 4Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 5Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 2Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 3Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 4
...ities combined with ease of use make the OM-5 Seri... or hospital-based urodynamics, the OM-5 is a comp...nt pressure, or urethral pressure profiles. Eight ...-5 flexible enough to meet the needs of all clinic...
...ities combined with ease of use make the OM-5 Seri... or hospital-based urodynamics, the OM-5 is a comp...nt pressure, or urethral pressure profiles. Eight ...-5 flexible enough to meet the needs of all clinic...
...ities combined with ease of use make the OM-5 Seri... or hospital-based urodynamics, the OM-5 is a comp...nt pressure, or urethral pressure profiles. Eight ...-5 flexible enough to meet the needs of all clinic...
...ities combined with ease of use make the OM-5 Seri... or hospital-based urodynamics, the OM-5 is a comp...nt pressure, or urethral pressure profiles. Eight ...-5 flexible enough to meet the needs of all clinic...
Medicine Products: